1622006-09-0
1622006-09-0 結(jié)構(gòu)式
基本信息
化合物RADIOPROTECTIN-1
Benzoic acid, 5-chloro-2-[[[4-(1,3-dioxo-1H-benz[de]isoquinolin-2(3H)-yl)butyl]amino]sulfonyl]-
物理化學(xué)性質(zhì)
常見問題列表
EC50: 25 nM (murine LPA 2 subtype)
Radioprotectin-1 is a potent agonist of LPA
2
with an EC
50
of 5 pM and functions as a full agonist at the human ortholog of LPA
2
.
Radioprotectin-1 (0-3 μM; 15 minutes) effectively reduces apoptosis induced by γ-irradiation and the radiomimetic drug Adriamycin in cells that expressed LPA
2
either endogenously or after transfection.
Cell Viability Assay
| Cell Line: | MEF cells , IEC-6 cells |
| Concentration: | 0 μM, 0.1 μM, 0.3 μM, 1.0 μM,3 μM |
| Incubation Time: | 15 minutes |
| Result: | Protected cells from apoptosis by γ-irradiation- and the radiomimetic chemotherapeutic Adiamycin. |
Radioprotectin-1 is a high-potency specific agonist of the murine LPA
2
GPCR .
Radioprotectin-1 (0.1 mg/kg, 0.3 mg/kg; s.c.; every 12 hours; for 3 days) decreases the mortality of C57BL/6 mice in models of the hematopoietic acute radiation syndromes (HE-ARS) and gastrointestinal acute radiation syndromes (GI-ARS) .
Radioprotectin-1 exerts its radioprotective and radiomitigative action through specific activation of the upregulated LPA
2
GPCR in Lgr5
+
stem cells.
| Animal Model: | 8-10 weeks old C57BL/6 female mice bearing total body irradiation (TBI) |
| Dosage: | 0.1 mg/kg, 0.3 mg/kg |
| Administration: | Subcutaneous injection; every 12 hours; for 3 days |
| Result: | Decreased mortality of C57BL/6 mice in models of the HE-ARS and the GI-ARS. |